uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
A Pharmacokinetic and Dosing Study of Intravenous Insulin-Like Growth Factor-I and IGF-Binding Protein-3 Complex to Preterm Infants
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Show others and affiliations
2009 (English)In: Pediatric Research, ISSN 0031-3998, E-ISSN 1530-0447, Vol. 65, no 5, 574-579 p.Article in journal (Refereed) Published
Abstract [en]

In preterm infants, low levels of Insulin like growth factor I (IGF-I) have been associated with impaired growth and retinopathy of prematurity. Our objective was to study safety and pharmacokinetics of i.v. administered rhIGF-I with its binding protein 3 (rhIGFBP-3) to preterm infants. At 3 d chronological age, an i.v. 3 h infusion of rhIGF-1/rhIGFBP-3 was administered followed by serial measurements of IGF-I and IGFBP-3. Infants were evaluated for physiologic safety measurements. The individual dose of rhIGF-I ranged from I to 12 mu g/kg. The study was conducted at Queen Silvia Children's Hospital, Gothenburg, Sweden, between January and November 2007. Five patients (3 F) with mean (range) post menstrual age 27 wk (26-29) and birth weight 1022 g (810-1310) participated. IGF-I and IGFBP-3 levels before infusion were median (range) 18 (12-28) and 771 (651-1047) ng/mL, respectively. Immediately after study drug infusion, serum IGF-I and IGFBP-3 levels were 38 (25-59) and 838 (754-1182) ng/mL, respectively. Median (range) half-life for IGF-I and IGFBP-3 was 0.79 (0.59-1.42) and 0.87 (0.85-0.94) hours, respectively. Blood glucose, insulin, sodium, potassium, and physiologic safety measures were within normal ranges. The rhIGF-1/rhIGFBP-3 equimolar proportion was effective in increasing serum IGF-I levels and administration under these study conditions was safe and well tolerated.

Place, publisher, year, edition, pages
2009. Vol. 65, no 5, 574-579 p.
National Category
Pharmaceutical Sciences
URN: urn:nbn:se:uu:diva-152100DOI: 10.1203/PDR.0b013e31819d9e8cISI: 000265448700017OAI: oai:DiVA.org:uu-152100DiVA: diva2:412490
Available from: 2011-04-25 Created: 2011-04-25 Last updated: 2011-04-25Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Pediatric Research
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 150 hits
ReferencesLink to record
Permanent link

Direct link